The board of directors of Aqua Bio Technology ASA (the "Company") has resolved a share capital increase after having received a notification of exercise of options in the Company.
The Company's share capital will be increased with a total of NOK 33 332 pursuant to the resolution, by issuance of 8 333 new shares. The Company's share capital will after completion of the share capital increase be NOK 27 608 000 divided on 6 902 000 shares, each with a nominal value of NOK 4. Each share carries the right to cast one vote in a general meeting of the Company.
For further information, please contact:
| Arvid Lindberg, CEO | |
| E-mail: | arvid@aquabiotech.no |
| Telephone: | +47 9824 5410 |
About Aqua Bio Technology ASA (www.aquabiotech.no)
Aqua Bio Technology ASA (ABT) develops, produces and markets patented ingredients and technologies to the international cosmetic and skin care industry. ABT's ingredients Aquabeautine XL(TM), Dermaclarine(TM) and Beauty Propelline(TM) are marine solutions derived from the hatching fluid of salmon, while Oceanx(TM) Oil in Serum is based on extract from seaweed. ABT is listed on the Oslo Stock Exchange's Axess market.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.